GlassScriptPhysician profile
Angela Beth Wilson
NPI 1225652191
$11,237.67
in general payments reported to CMS, 2019-2025
25 companies · $2,184 in 2025
The $2,184 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,471 · 2022: $2,404 · 2023: $2,170 · 2024: $3,009 · 2025: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,357 · Education: $5.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,356.94 |
| Education | $5.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,985.48 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,485.86 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,428.35 | 2022-2025 | Spravato, Invega Sustenna, Invega |
| Otsuka America Pharmaceutical, INC. | $1,395.03 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,192.55 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $567.07 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $334.28 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $299.07 | 2022-2024 | Azstarys |
| Lundbeck LLC | $280.70 | 2021-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $235.49 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $199.25 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $122.60 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $119.14 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $116.77 | 2023-2025 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $104.28 | 2024-2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $97.35 | 2023-2025 | Auvelity |
| Masimo Corporation | $67.05 | 2022 | |
| Almatica Pharma LLC | $51.26 | 2025 | Loreev Xr |
| Avion Pharmaceuticals | $36.78 | 2023 | Methylphenidate Hydrochloride |
| Neuronetics, INC. | $26.70 | 2024 | Neurostar Tms Therapy System |
| Sage Therapeutics, LLC | $22.79 | 2025 | Zurzuvae |
| Tris Pharma INC | $20.43 | 2024 | Dyanavel Xr |
| Eisai INC. | $17.56 | 2021 | |
| Owp Pharmaceuticals, INC. | $16.21 | 2025 | Subvenite |
| Sunovion Pharmaceuticals INC. | $15.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.